Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
Antibody therapies that target Aβ in AD continue to generate interest with recent approvals and new potential treatments in development.
- Antibody therapies that target Aβ in AD continue to generate interest with recent approvals and new potential treatments in development.
- However, it has been a challenge to specifically target toxic oligomers since they are the least abundant form of Aβ in the brain.
- In preclinical studies, ProMIS Neurosciences’ lead candidate, PMN310, has demonstrated its ability to selectively target pathogenic Aβ oligomers without unproductive binding to non-toxic monomers or plaque.
- “We believe these encouraging data help differentiate our lead therapeutic candidate, PMN310, from other Aβ-directed antibodies.